Stacks Image 491


  • November 2022 - Our spin-off DDC makes an important step forward gaining funding of 1.5 million euros by Utopia SIS, a society of investments focussing on biomedical healthcare promoted by Fondazione Golinelli, Fondazione Sardegna and by Antonio Falcone, the executive Vice President.

  • July 2022 - Our project "learning a lesson: fighting SARS-CoV 2 Infection and get ready for other future PandEmic scenaRios" (acronym: VIPER) was selected by NATO Science for Peace and Security (SPS) Program for fundings! Check Prof Lolli's interview at the local News in our home page.


  • November 2021- Our PhD student Chiara Vigato has been selected as one of the Best Graduated students of the University of Torino, Academic Year 2018-2019. Her Master's Thesis titled "Application of a Bioisosteric Approach in the Design of Innovative Inhibitors of Aldo-Keto Reductase (AKR1C3) to Target Prostate Cancer" has been awarded as the best experimental Thesis of the whole Department of Drug Science and Technology of that year! Here the link.

  • September 2021- You can find us at VIII EFMC-YMCS symposium September 9th - 10th!

  • August 2021- You can find us at XXVI EFMC-ISMC symposium from August 29th to September 2nd!

  • July 2021- Our research line dedicated to design and validation of innovative Dihydroorotate Dehydrogenase (hDHODH) inhibitors as Broad-Spectrum Antiviral Agents has been founded by the INFRA-P2 COVID program, supported by Regione Piemonte, with 1M Euro.  The project SILK, that involves four departments of the University of Turin (DSTF, DBIOS (Giorgio Gribaudo), DNS (Stefano Gotti) and DMS (Giovanni Di Perri)) and two private Italian research institutions (Fondazione Edo Tempia (Giovanna Chiorino) and Gem Forlab (Barbara Canepa)), will lead our compound called MEDS433 to the threshold of human experimentation for COVID-19.  We have published in these months the SILK extensive preparatory work (see:,,, check it out!

  • May 2021- Here our interview for Biotecnologie News about our spin-off DDC.

  • May 2021- our new paper about development of new generation hDHODH inhibitors has been published on JMC! Click here for the preview.

  • May 2021- The paper named "Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication" has been published on Antiviral Research. Click here for the article.

  • April 2021 the 13th Young Medicinal Chemist Symposium from the 26th to the 29th of April., Dr. Stefano Sainas presented an oral communication titled: "The Inhibition of human DHODH by M433 Leads to Differentiation and Apoptosis in Acute Myeloid Leukemia".

  • March 2021- our new article "The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia" has been published in Cancers as part of the Special Issue Combination Therapies in Cancers and is available online.

  • January 2021- Our chapter "Hydroxyazoles as acid isosteres and their drug design applications—Part 2: Bicyclic systems" has been published in the book "Advances in Heterocyclic Chemistry" (see here)


  • April 6th, 2018 - Alessandro Giraudo will defend his Double Degree PhD (UniTO - University of Copenhagen, DK) titled: Development of GABA-A receptor ligands using a bioisosteric approach. Tutors: dr. Marco L. Lolli and prof Bente Frolund.

  • March 21th, 2018 4.10 PM - The hDHODH project will be finally orally presented by Marco Lolli at the 255th ACS National Meeting, New Orleans, LA, March 18-22, 2018 (USA). See here the abstract.

  • February 2018 - The Grant4Target project nicknamed BLAST, supported by Bayer, dedicated to target MoDHODH officially starts.

  • February 2018 - The project nicknamed NACTUS, supported by Fondazione CRT and dedicated to target AKR1C3 inside prostate cancer, officially starts.


  • September 2017 - The hDHODH project story will be presented by Marco Lolli at the Italian Chemistry Society Meeting SCI - 2017 in Paestum. The speech title will be titled: Potent human dihydroorotate dehydrogenase (hDHODH) inhibitors obtained by scaffold-hopping approaches: from the theoretical design to the in vivo evaluation. Here the accepted abstract.

  • June 2017 - The Pin1 manuscript finally appeared on Nature Communication! Here for download a copy of it.

  • March 3, 2017 - the call for PhD in Medicinal Chemistry dedicated to the hDHODH line is OPEN! Deadline for submission: March 24th, 2017. See here for general information, here for specific call details and here (see page 15, project 4) for the title of our project dedicated to hDHODH.

  • February 24, 2017 - Istituto di Ricerca Farmacologiche Mario Negri - Milano. Marco Lolli presented a speech titled: "Targeting AKR1C3 on prostate cancer: an opportunity to design effective drugs? Design innovative AKR1C3 inhibitors by reaching high quality "druggable" chemical space". (see here for the speech details)

  • The CRPCcare results on AKR1C3 were presented by Marco Lolli and Agnese Pippione at the Prostate Cancer and the Tumour Microenvironment Workshop at the Cardiff University (Cardiff, UK) (see here)

  • The hDHODH manuscript describing the Stefano Sainas's PhD Thesis is in press on EJMC! (here)


  • Marco Lolli and Giovanna Chiorino, from Tumor Pharmacogenomic Laboratory of the Fondazione Edo e Elvo Tempia, presented at Hack#UniTo (Campus Einaudi, November 22th, 2016, see here) the CRPCcare project.